According to CDC, There Are 86 Million People in the U.S. That Have Elevated Blood Glucose Levels; According to the IDF, There Are 382 Million People Worldwide Living With Elevated Blood Sugar and That Number Is Projected to Increase to 592 Million by 2035
MANCHESTER, NH -- (Marketwired) -- 11/03/14 -- Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels, announced that Benchworks SD, LLC launched the branding of sugardown® in North America. sugardown® is a new natural dietary supplement product that helps people maintain healthy blood sugar levels. sugardown® is the first chewable tablet of its kind. It was designed for people who are committed to a balanced diet and exercise to help keep their blood sugar levels healthy.
According to statistics published by the Center for Disease Control, there are 86 million people in the United States who have elevated blood glucose levels. These people may benefit by adding sugardown® to their diet and exercise regimens. According to the International Diabetes Federation, there are 382 million people worldwide living with elevated blood sugar and that number is projected to increase to 592 million by 2035.
Boston Therapeutics' marketing plan for sugardown® is to out-license marketing rights to strategic partners in their jurisdictions of expertise. The Company entered into an agreement with Advance Pharmaceutical Co. Ltd. (APC), our Hong Kong-based strategic partner to develop markets for sugardown® in Hong Kong, China and Macau. This year to date, the Company has sold more than 20,000 bottles of sugardown®to APC to test the Asian market. As part of the plan to increase sales, the Company recently entered into a strategic marketing collaboration with Benchworks SD, LLC, a leading branding and marketing agency, aimed at driving brand awareness and growing sales of sugardown® among the large pre-diabetic population in North America.
The main ingredient in sugardown® is made from naturally occurring plant-based mannans (galactomannans) that when combined with a healthy lifestyle and diet have the ability to regulate digestive enzymes which in turn promotes healthy digestion, optimal sugar absorption and supports healthy postprandial glucose levels.
The unique chewable tablet formulation works by blocking digestive enzymes starting in the mouth and promoting healthy digestion and optimal sugar absorption.
Kristen Kim, a 47-year old woman from San Jose, California, said that what ultimately sold her on the idea of trying sugardown® was the impressive science behind the product, which was formulated by one of the world's leading complex carbohydrate scientists. "I read everything on the sugardown® web site and was impressed that the product was a result of about 30 years of research, development, and testing. I also liked that it was a 'dietary supplement' and not a prescription medication."
Kristen continued, saying, "I usually take two sugardown® tablets before meals, both at home and at restaurants. I always have a full bottle in my tote bag."
David Platt, Ph.D., CEO of Boston Therapeutics, manufacturer of sugardown®, commented, saying, "As an inventor of sugardown®, knowing that we have a natural dietary supplement that can help make a difference in people's lives is very exciting. People who want to maintain a healthy blood sugar level want some options in their life: a little freedom to choose, and that is what sugardown® is all about."
Benchworks LLC, based in Chestertown, Maryland, specializes in branding and positioning products by developing marketing promotions, product launches and online solutions for corporate clients ranging from mid-sized firms to Fortune 500 companies. Its client roster includes leading life science companies such as Pfizer Pharmaceuticals, Shire Pharmaceuticals, and Noven Pharmaceuticals, as well as other industry leaders such as Coca-Cola, Chrysler and CB Richard Ellis Inc. Additional information is available at www.benchworks.com.
About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases. Additional information is available at www.bostonti.com.
Cautionary Note Regarding Forward Looking Statements
This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.
Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.
© Boston Therapeutics, Inc. All rights reserved.
Source: Boston Therapeutics